• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Amazon’s PillPack deal puts a bull’s-eye on drug distributors and pharmacies

Share:

July 7, 2018

Amazon.com Inc.’s deal to buy online pharmacy PillPack put a dent in the stock prices of major drug distributors and pharmacies.

Amazon announced plans Thursday morning to buy the Boston-based startup for an undisclosed amount. The Wall Street Journal put the price at $1 billion in cash, citing unnamed sources.

McKesson was down more than six percent to about $136 per share, while AmerisourceBergen Corp.fell more than 4 percent to about $86 per share.

Walgreens Boots Alliance dropped nearly 10 percent to less than $60 per share and CVS Health Corp.’s share price decreased more than 6 percent to about $65.75.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

West Monroe Partners Senior Director of Life Sciences Ed Francis expects this to be Amazon’s first incremental step into the prescription drug business, with PillPack’s delivery capability to be followed by expansion into larger parts of the industry such as in-store pharmacies.

“Distributors will likely feel the impact first, as Amazon’s mail-order prescriptions take volume away from them,” he said. “Pharmacies will also start to feel the effects because a big part of their business comes from customers buying a cookie or some other impulse buy in addition to the drug they came into the store to pick up.”

Amazon recently added medical supplies and equipment to its online offerings, but hasn’t secured government permits to sell prescription drugs. PillPack holds pharmacy licenses in all 50 states.

Amazon named Dr. Atul Gawande CEO of its budding health care venture with JPMorgan Chase and Berkshire Hathaway last week. That business will also be headquartered in Boston.

Amazon took a similar approach with groceries. It founded AmazonFresh delivery 11 years ago, later expanding into same-day grocery delivery through grocery partners and acquiring Whole Foods last year.

“Unless you’re a producer of product, I think you’re threatened,” Francis said. “If you make drugs or medical supplies and you’re not on board with Amazon yet, you probably should be.”

The deal is expected to close in the second half of 2018.

Date: July 9, 2018

Source: bizjournals

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • 3 Use Cases for Artificial Intelligence in Healthcare3 Use Cases for Artificial Intelligence in Healthcare
  • HeartBeam Announces Acquisition of LIVMOR AssetsHeartBeam Announces Acquisition of LIVMOR Assets
  • Former Kaiser Permanente CTO Mike Sutten Joins Innovaccer as Chief Digital OfficerFormer Kaiser Permanente CTO Mike Sutten Joins Innovaccer as Chief Digital Officer
  • Sharecare Acquires Visualize Health to Drive Better Patient OutcomesSharecare Acquires Visualize Health to Drive Better Patient Outcomes
  • Transcat Establishes Calibration Presence in Ireland with Acquisition of Complete Calibrations and Acquires Cleveland-Based e2b CalibrationTranscat Establishes Calibration Presence in Ireland with Acquisition of Complete Calibrations and Acquires Cleveland-Based e2b Calibration
  • PA Consulting enhances global innovation and product design capability through acquisition of Essential DesignPA Consulting enhances global innovation and product design capability through acquisition of Essential Design
  • Thermo Fisher Scientific Completes Acquisition of Advanced Bioprocessing from BDThermo Fisher Scientific Completes Acquisition of Advanced Bioprocessing from BD
  • Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of SchizophreniaBoehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications